O Shaughnessy Asset Management LLC Buys 136 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

O Shaughnessy Asset Management LLC increased its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXXGet Rating) by 3.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 4,280 shares of the company’s stock after acquiring an additional 136 shares during the quarter. O Shaughnessy Asset Management LLC’s holdings in IDEXX Laboratories were worth $1,746,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of IDXX. BlackRock Inc. boosted its position in shares of IDEXX Laboratories by 4.2% during the third quarter. BlackRock Inc. now owns 8,792,300 shares of the company’s stock worth $2,864,533,000 after acquiring an additional 358,427 shares during the last quarter. Winslow Capital Management LLC raised its stake in IDEXX Laboratories by 31.4% during the fourth quarter. Winslow Capital Management LLC now owns 873,084 shares of the company’s stock valued at $356,183,000 after purchasing an additional 208,387 shares in the last quarter. Brown Advisory Inc. raised its stake in IDEXX Laboratories by 16.4% during the third quarter. Brown Advisory Inc. now owns 1,212,028 shares of the company’s stock valued at $394,880,000 after purchasing an additional 170,834 shares in the last quarter. Echo Street Capital Management LLC raised its stake in IDEXX Laboratories by 65.7% during the third quarter. Echo Street Capital Management LLC now owns 421,416 shares of the company’s stock valued at $137,297,000 after purchasing an additional 167,164 shares in the last quarter. Finally, State Street Corp raised its stake in IDEXX Laboratories by 3.6% during the third quarter. State Street Corp now owns 3,784,353 shares of the company’s stock valued at $1,232,942,000 after purchasing an additional 132,091 shares in the last quarter. Institutional investors own 87.90% of the company’s stock.

IDEXX Laboratories Trading Down 1.2 %

IDXX stock opened at $458.06 on Friday. The company has a market capitalization of $37.97 billion, a PE ratio of 55.12, a P/E/G ratio of 2.78 and a beta of 1.19. IDEXX Laboratories, Inc. has a 12 month low of $317.06 and a 12 month high of $515.79. The firm’s 50-day moving average is $483.00 and its 200 day moving average is $461.49. The company has a debt-to-equity ratio of 0.83, a current ratio of 1.08 and a quick ratio of 0.71.

Insider Buying and Selling

In related news, Director Jonathan W. Ayers sold 10,000 shares of the firm’s stock in a transaction dated Thursday, May 18th. The shares were sold at an average price of $489.23, for a total value of $4,892,300.00. Following the transaction, the director now owns 137,039 shares of the company’s stock, valued at approximately $67,043,589.97. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other IDEXX Laboratories news, Director Sophie V. Vandebroek sold 2,187 shares of the stock in a transaction dated Thursday, May 4th. The shares were sold at an average price of $469.02, for a total transaction of $1,025,746.74. Following the transaction, the director now directly owns 872 shares in the company, valued at approximately $408,985.44. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Jonathan W. Ayers sold 10,000 shares of the stock in a transaction dated Thursday, May 18th. The stock was sold at an average price of $489.23, for a total transaction of $4,892,300.00. Following the transaction, the director now owns 137,039 shares in the company, valued at $67,043,589.97. The disclosure for this sale can be found here. Insiders have sold 13,187 shares of company stock valued at $6,402,047 in the last 90 days. Company insiders own 2.11% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the stock. StockNews.com assumed coverage on shares of IDEXX Laboratories in a research note on Thursday, May 18th. They set a “buy” rating on the stock. Morgan Stanley upped their price target on shares of IDEXX Laboratories from $543.00 to $590.00 and gave the company an “overweight” rating in a research note on Thursday, March 23rd. JPMorgan Chase & Co. upped their price target on shares of IDEXX Laboratories from $525.00 to $550.00 and gave the company an “overweight” rating in a research note on Tuesday, February 7th. Barclays increased their target price on shares of IDEXX Laboratories from $582.00 to $590.00 and gave the company an “overweight” rating in a research note on Wednesday, February 8th. Finally, Atlantic Securities increased their target price on shares of IDEXX Laboratories from $470.00 to $600.00 and gave the company an “overweight” rating in a research note on Tuesday, February 7th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $527.86.

IDEXX Laboratories Profile

(Get Rating)

IDEXX Laboratories, Inc engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy, and water testing markets. It operates through the following segments: Companion Animal Group (CAG), Water Quality Products (Water), Livestock, Poultry, and Dairy (LPD), and Other.

Read More

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXXGet Rating).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.